{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:06:06Z","timestamp":1784196366681,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05064-w","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:41:21Z","timestamp":1772077281000},"page":"2835-2847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-1\/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for ARPI-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer: a pooled analysis of KEYNOTE-921 and CheckMate 7DX trials"],"prefix":"10.1007","volume":"58","author":[{"given":"Qi","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"1","key":"5064_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"5064_CR2","first-page":"485","volume":"75","author":"TB Kratzer","year":"2025","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL (2025) Prostate cancer statistics, 2025. CA Cancer J Clin 75(6):485\u2013497","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5064_CR3","first-page":"e247047","volume":"23","author":"D Sentana-Lledo","year":"2024","unstructured":"Sentana-Lledo D, Saraf A, Morgans AK (2024) Symptom burden and survivorship care for patients with prostate cancer on androgen deprivation therapy. J Natl Compr Canc Netw 23(1):e247047","journal-title":"J Natl Compr Canc Netw"},{"issue":"21","key":"5064_CR4","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-24-0803","volume":"30","author":"JL Jensen","year":"2024","unstructured":"Jensen JL, Bobek O, Chan ICC, Miller BC, Hillman DW, Heller G, Druley T, Armstrong AJ, Morris MJ, Milowsky MI, Beltran H, Bolton KL, Coombs CC (2024) Clonal hematopoiesis and clinical outcomes in metastatic castration-resistant prostate cancer patients given androgen receptor pathway inhibitors (Alliance A031201). Clin Cancer Res 30(21):4910\u20134919","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5064_CR5","doi-asserted-by":"publisher","first-page":"102215","DOI":"10.1016\/j.xcrm.2025.102215","volume":"6","author":"TM Severson","year":"2025","unstructured":"Severson TM, Minnee E, Zhu Y, Schuurman K, Nguyen HM, Brown LG et al (2025) Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer. Cell Rep Med 6(7):102215","journal-title":"Cell Rep Med"},{"issue":"1","key":"5064_CR6","doi-asserted-by":"publisher","first-page":"10648","DOI":"10.1038\/s41467-024-54847-1","volume":"15","author":"TP Knutson","year":"2024","unstructured":"Knutson TP, Luo B, Kobilka A, Lyman J, Guo S, Munro SA et al (2024) AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients. Nat Commun 15(1):10648","journal-title":"Nat Commun"},{"issue":"20","key":"5064_CR7","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO-25-00007","volume":"43","author":"R Garje","year":"2025","unstructured":"Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM et al (2025) Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol 43(20):2311\u20132334","journal-title":"J Clin Oncol"},{"issue":"28","key":"5064_CR8","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1200\/JCO-24-02637","volume":"43","author":"G Leone","year":"2025","unstructured":"Leone G, Wong YNS, Jones RJ, Sankey P, Josephs DH, Crabb SJ et al (2025) Nivolumab and ipilimumab for metastatic castration-resistant prostate cancer with an immunogenic signature: the multicenter, two-cohort, phase II NEPTUNES study. J Clin Oncol 43(28):3070\u20133080","journal-title":"J Clin Oncol"},{"issue":"14","key":"5064_CR9","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1200\/JCO-24-02402","volume":"43","author":"SF Slovin","year":"2025","unstructured":"Slovin SF (2025) Immune checkpoint combos in metastatic castration-resistant prostate cancer: where are we going, what are we doing, and why? J Clin Oncol 43(14):1617\u20131619","journal-title":"J Clin Oncol"},{"issue":"1","key":"5064_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","volume":"82","author":"EY Yu","year":"2022","unstructured":"Yu EY, Kolinsky MP, Berry WR, Retz M, Mourey L, Piulats JM et al (2022) Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study. Eur Urol 82(1):22\u201330","journal-title":"Eur Urol"},{"issue":"1","key":"5064_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1470-2045(25)00566-2","volume":"27","author":"K Fizazi","year":"2026","unstructured":"Fizazi K, Saad F, Alonso-Gordoa T, \u017burawski B, Barth\u00e9l\u00e9my P, Voog E et al (2026) Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. Lancet Oncol 27(1):68\u201378","journal-title":"Lancet Oncol"},{"issue":"14","key":"5064_CR12","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak DP, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L et al (2025) Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial. J Clin Oncol 43(14):1638\u20131649","journal-title":"J Clin Oncol"},{"issue":"1","key":"5064_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"key":"5064_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"4","key":"5064_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A (2011) GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64(4):380\u2013382","journal-title":"J Clin Epidemiol"},{"key":"5064_CR16","doi-asserted-by":"publisher","first-page":"102818","DOI":"10.1016\/j.ctrv.2024.102818","volume":"130","author":"E Akkus","year":"2024","unstructured":"Akkus E, Arslan \u00c7, \u00dcr\u00fcn Y (2024) Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: insights and perspectives. Cancer Treat Rev 130:102818","journal-title":"Cancer Treat Rev"},{"key":"5064_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003309","author":"J Liu","year":"2025","unstructured":"Liu J, Kang YM, Feng YG, Zhang C, Chen WZ (2025) Comparison of complications and oncology outcomes of immunotherapy alone and combination in metastatic castration-resistant prostate cancer (mCRPC): a systematic review and meta-analysis. Int J Surg. https:\/\/doi.org\/10.1097\/JS9.0000000000003309","journal-title":"Int J Surg"},{"issue":"33","key":"5064_CR18","doi-asserted-by":"publisher","first-page":"43257","DOI":"10.1021\/acsami.4c07072","volume":"16","author":"C Wu","year":"2024","unstructured":"Wu C, Feng D, Xu H, He Z, Hou J (2024) Optimized bionic drug-delivery-inducing immunogenic cell death and cGAS-STING pathway activation for enhanced photodynamic-chemotherapy-driven immunotherapy in prostate cancer. ACS Appl Mater Interfaces 16(33):43257\u201343271","journal-title":"ACS Appl Mater Interfaces"},{"issue":"12","key":"5064_CR19","doi-asserted-by":"publisher","first-page":"e012690","DOI":"10.1136\/jitc-2025-012690","volume":"13","author":"K Rawat","year":"2025","unstructured":"Rawat K, Punia V, Mathews P, McCoy S, Song W, Saeed MA et al (2025) Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer. J Immunother Cancer 13(12):e012690","journal-title":"J Immunother Cancer"},{"issue":"15","key":"5064_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/pros.24213","volume":"81","author":"BL Sun","year":"2021","unstructured":"Sun BL (2021) Immunotherapy in treatment of metastatic prostate cancer: an approach to circumvent immunosuppressive tumor microenvironment. Prostate 81(15):1125\u20131134","journal-title":"Prostate"},{"key":"5064_CR21","doi-asserted-by":"publisher","first-page":"175883592513875","DOI":"10.1177\/17588359251387570","volume":"17","author":"R Ren","year":"2025","unstructured":"Ren R, Wang Y, Wang Q, Lu B, Gao Y, Li H et al (2025) Real-world evidence for immunotherapy in the first-line or subsequent-line setting in extensive-stage small-cell lung cancer. Ther Adv Med Oncol 17:17588359251387570","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"5064_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00667-y","volume":"14","author":"R Ran","year":"2025","unstructured":"Ran R, Chen X, Yang J, Xu B (2025) Immunotherapy in breast cancer: current landscape and emerging trends. Exp Hematol Oncol 14(1):77","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"5064_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 38(5):395\u2013405","journal-title":"J Clin Oncol"},{"issue":"1","key":"5064_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N et al (2022) Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med 28(1):144\u2013153","journal-title":"Nat Med"},{"issue":"7","key":"5064_CR25","doi-asserted-by":"publisher","first-page":"e001758","DOI":"10.1136\/jitc-2020-001758","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang Z, Zhang X, Li W, Su Q, Huang Z, Zhang X et al (2021) ATM\/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. J Immunother Cancer 9(7):e001758","journal-title":"J Immunother Cancer"},{"key":"5064_CR26","doi-asserted-by":"publisher","first-page":"102941","DOI":"10.1016\/j.ctrv.2025.102941","volume":"136","author":"G Belge Bilgin","year":"2025","unstructured":"Belge Bilgin G, Lucien-Matteoni F, Chaudhuri AA, Orme JJ, Childs DS, Muniz M et al (2025) Current and future directions in theranostics for neuroendocrine prostate cancer. Cancer Treat Rev 136:102941","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"5064_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.euo.2023.11.019","volume":"7","author":"X Ni","year":"2024","unstructured":"Ni X, Wu J, Pan J, Li X, Fang B, Wei Y et al (2024) Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer. Eur Urol Oncol 7(4):897\u2013905","journal-title":"Eur Urol Oncol"},{"issue":"8048","key":"5064_CR28","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A et al (2025) Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature 637(8048):1207\u20131217","journal-title":"Nature"},{"issue":"1","key":"5064_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","volume":"23","author":"Q Liu","year":"2024","unstructured":"Liu Q, Guan Y, Li S (2024) Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: the \u201call-around warrior\u201d in immunotherapy. Mol Cancer 23(1):183","journal-title":"Mol Cancer"},{"issue":"3","key":"5064_CR30","doi-asserted-by":"publisher","first-page":"e010928","DOI":"10.1136\/jitc-2024-010928","volume":"13","author":"TR Cottrell","year":"2025","unstructured":"Cottrell TR, Lotze MT, Ali A, Bifulco CB, Capitini CM, Chow LQM et al (2025) Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. J Immunother Cancer 13(3):e010928","journal-title":"J Immunother Cancer"},{"issue":"7","key":"5064_CR31","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1097\/JS9.0000000000002528","volume":"111","author":"S Liu","year":"2025","unstructured":"Liu S, Li X, Wu C, Yao L, Dong H, Zhang H et al (2025) Efficacy and safety of neoadjuvant ICI combined with chemotherapy in breast cancer from the perspective of a privileged population: a systematic review and meta-analysis. Int J Surg 111(7):4726\u20134735","journal-title":"Int J Surg"},{"issue":"5","key":"5064_CR32","doi-asserted-by":"publisher","first-page":"e011140","DOI":"10.1136\/jitc-2024-011140","volume":"13","author":"C Morgan","year":"2025","unstructured":"Morgan C, Kurland J, Patel M, O\u2019Brien C, Concepcion P, Doherty GJ et al (2025) Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers. J Immunother Cancer 13(5):e011140","journal-title":"J Immunother Cancer"},{"key":"5064_CR33","doi-asserted-by":"publisher","first-page":"102847","DOI":"10.1016\/j.ctrv.2024.102847","volume":"131","author":"G Villacampa","year":"2024","unstructured":"Villacampa G, Cresta Morgado P, Carit\u00e0 L, Navarro V, Pascual T, Dienstmann R (2024) Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: a systematic review and meta-analysis. Cancer Treat Rev 131:102847","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"5064_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma P, Pachynski RK, Narayan V, Fl\u00e9chon A, Gravis G, Galsky MD et al (2020) Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell 38(4):489-499.e3","journal-title":"Cancer Cell"},{"issue":"4","key":"5064_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.eururo.2022.01.028","volume":"81","author":"Z Wu","year":"2022","unstructured":"Wu Z, Chen Q, Qu L, Li M, Wang L, Mir MC et al (2022) Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta-analysis. Eur Urol 81(4):414\u2013425","journal-title":"Eur Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05064-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05064-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05064-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:18:49Z","timestamp":1784193529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05064-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["5064"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05064-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}